REMEGEN (09995) expects a net profit attributable to shareholders of approximately 4.7 billion yuan in mid-2026.

REMEGEN (09995) announced that it expects mid-2026 operating revenue of approximately RMB 5.85 billion, an increase of about 433% year-on-year. It is anticipated that the net profit attributable to shareholders of the parent company for mid-2026 will be approximately RMB 4.7 billion, achieving a turnaround from loss to profit compared to the same period last year. By mid-2026, the companys core products, Tislelizumab and Vedolizumab, continue to see growth in domestic sales revenue; at the same time, the company has signed an exclusive licensing agreement for RC148 with AbbVie Inc. ("AbbVie"), granting AbbVie exclusive rights for the development, production, and commercialization of RC148 outside the Greater China region, leading to a substantial increase in technology licensing revenue. It is expected to achieve profitability in the first half of 2026.